Qiagen NV (QGEN)
41.86
-0.03
(-0.07%)
USD |
NYSE |
Jun 21, 16:00
41.85
-0.01
(-0.02%)
Pre-Market: 20:00
Qiagen Accounts Receivable (Quarterly): 343.89M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 343.89M |
December 31, 2023 | 381.88M |
September 30, 2023 | 326.69M |
June 30, 2023 | 312.60M |
March 31, 2023 | 317.24M |
December 31, 2022 | 323.75M |
September 30, 2022 | 310.98M |
June 30, 2022 | 334.57M |
March 31, 2022 | 372.38M |
December 31, 2021 | 362.13M |
September 30, 2021 | 359.52M |
June 30, 2021 | 366.15M |
March 31, 2021 | 371.69M |
December 31, 2020 | 380.52M |
September 30, 2020 | 373.06M |
June 30, 2020 | 372.47M |
March 31, 2020 | 362.05M |
December 31, 2019 | 385.12M |
September 30, 2019 | 358.84M |
June 30, 2019 | 364.89M |
March 31, 2019 | 341.44M |
December 31, 2018 | 351.61M |
September 30, 2018 | 314.35M |
June 30, 2018 | 314.67M |
March 31, 2018 | 331.85M |
Date | Value |
---|---|
December 31, 2017 | 329.14M |
September 30, 2017 | 294.97M |
June 30, 2017 | 278.39M |
March 31, 2017 | 250.86M |
December 31, 2016 | 278.24M |
September 30, 2016 | 260.04M |
June 30, 2016 | 254.78M |
March 31, 2016 | 257.09M |
December 31, 2015 | 273.85M |
September 30, 2015 | 244.55M |
June 30, 2015 | 245.74M |
March 31, 2015 | 231.69M |
December 31, 2014 | 265.23M |
September 30, 2014 | 257.10M |
June 30, 2014 | 248.25M |
March 31, 2014 | 244.83M |
December 31, 2013 | 259.71M |
September 30, 2013 | 236.43M |
June 30, 2013 | 247.97M |
March 31, 2013 | 244.36M |
December 31, 2012 | 250.73M |
September 30, 2012 | 220.98M |
June 30, 2012 | 217.57M |
March 31, 2012 | 231.94M |
December 31, 2011 | 230.77M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
310.98M
Minimum
Sep 2022
385.12M
Maximum
Dec 2019
354.02M
Average
362.09M
Median
Accounts Receivable (Quarterly) Benchmarks
MoonLake Immunotherapeutics | -- |
LENZ Therapeutics Inc | -- |
Thermo Fisher Scientific Inc | 7.931B |
argenx SE | -- |
uniQure NV | 10.72M |